Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232985 | 0.78 | GRM2 (0.55) | GRM2GRM3TSHRSMN1; SMN2 | |
| SCHEMBL14932087 | 0.77 | TSHR (0.41) | GRM2GRM3KDM4EALDH1A1TSHR | |
| SCHEMBL232123 | 0.77 | TSHR (0.41) | GRM2GRM3KDM4EALDH1A1TSHR | |
| SCHEMBL232984 | 0.76 | GRM2 (0.56) | GRM2GRM3TSHRSMN1; SMN2 | |
| SCHEMBL514523 | 0.75 | GRM2 (0.70) | GRM2GRM3 | |
| SCHEMBL4967909 | 0.75 | GRM2 (0.70) | GRM2GRM3 | |
| SCHEMBL4967900 | 0.75 | GRM2 (0.70) | GRM2GRM3 | |
| SCHEMBL14932135 | 0.74 | GRM2 (0.61) | GRM2GRM3 | |
| SCHEMBL230228 | 0.74 | GRM2 (0.61) | GRM2GRM3 | |
| SCHEMBL5961906 | 0.73 | GRM2 (0.80) | GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | claimed |
| EP-1459765-B1 | 6-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-7157594-B2 | 6-Fluorobicyclo[3.1.0]hexane derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| EP-1459765-A1 | 6-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | GRM2 1646/4885GRM3 2446/4885KDM4E 196/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | GRM2 2016/4885GRM3 2368/4885KDM4E 363/4885 |
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | GRM1, GRM2, GRM6 | GRM2 2/4885GRM3 4/4885KDM4E 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.